The FDA Wants to Talk About Psilocybin's Future. It Won't Touch Who's Using It Right Now.

This afternoon, from 12:30 to 4:30 p.m. Eastern, a room at the FDA’s White Oak campus in Silver Spring, Maryland, will spend four hours talking about who should be allowed to sit with you while you take psilocybin, how they should be trained, and what data the government needs to say yes. It’s the first public hearing the agency has ever held on the future of psychedelic medicine as a category — psilocybin, MDMA, LSD, all of it — and on paper it’s a milestone. There’s just one rule for the room: nobody gets to bring up whether any of this is currently legal.

The FDA convened a room to plan psilocybin’s medical future today while banning any discussion of the fact that seven million Americans already used it this year without one.

That’s not a rhetorical flourish — it’s the actual agenda. Marijuana Moment reports the hearing’s stated scope is provider training, credentialing, patient safety in supervised settings, and access — and that scheduling status under the Controlled Substances Act, decriminalization, and personal or religious use are explicitly off the table. Here’s the plain-language version of what that means: psilocybin stays in Schedule I, the government’s most restrictive drug category — same tier as heroin, defined as having no accepted medical use and high potential for abuse — no matter what gets said in that room today. If you’re a therapist in a state without a licensed program, nothing changes for you tomorrow morning. If you’re a patient, the hearing produces recommendations, not access.

Meanwhile, the thing the hearing won’t discuss is already the country’s actual psilocybin story. A JAMA Psychiatry paper from University of Colorado researchers, covered by the American Medical Association, put a number on it: more than 7 million adults ages 19 to 50 reported psilocybin use in the past year, and use among 35-to-50-year-olds grew sixfold between 2014 and 2024. The authors compare it directly to early cannabis legalization — enthusiasm and access outrunning regulation and evidence — and they’re blunt that this is happening with mushrooms most people buy or forage with zero quality control: potency in tested samples from decriminalized markets varies by as much as 20-fold, meaning a dose that’s mild for one batch can be a genuine crisis for the next. Poison control centers have felt it — calls involving hallucinogenic mushrooms climbed from 12% of psychedelic-related calls in 2012 to 32% a decade later.

So the split screen today is: a federal hearing engineering a careful, supervised, clinical on-ramp for a small future population of patients, running parallel to an enormous existing population that’s already using the drug with no on-ramp at all.

How we got two Americas on the same drug

The 1970 Controlled Substances Act placed psilocybin in Schedule I alongside LSD and MDMA, and for roughly three decades that scheduling didn’t just restrict use — it functionally halted human research, since getting approval to study a Schedule I compound was its own bureaucratic wall. Oregon cracked that wall open at the state level in 2020, when voters passed Measure 109 to license psilocybin service centers despite the federal prohibition remaining fully intact. The first centers opened in 2023; Colorado followed with its own regulated model in 2024, deliberately building in fixes — a lower-cost “micro” license tier, a ban on local opt-outs — for problems Oregon hit first. Today’s FDA hearing, 56 years after that original scheduling decision, is the federal government finally showing up to a conversation two states already started without it.

What that state-level head start actually produced is the closest thing anyone has to real-world safety data. OHSU researchers tracked 346 people through Oregon’s licensed centers from late 2024 into mid-2026 — not a curated clinical trial population, just people who showed up and paid for a supervised session. At one month, 91.5% reported some benefit and nearly two-thirds ranked the experience among the ten most meaningful of their lives; at three months, depression, anxiety, and PTSD symptoms had measurably eased. Only seven of the 346 reported a harmful experience by three months, and four people needed medical attention for an adverse reaction — out of 346, with no serious physical health events. Lead researcher Todd Korthuis said safety “was very similar to what we’ve seen with psychedelics in clinical settings.” That’s a real finding, and it’s worth naming its limits in the same breath: participants were healthier on average than typical clinical-trial patients, and cost and county-by-county restrictions mean this supervised version of psilocybin isn’t actually reachable for most people who might want it — including most of the 7 million already using it unsupervised.

What that state-level head start actually produced is the closest thing anyone has to real-world safety data.

The drug-development pipeline is moving in its own separate lane. Compass Pathways posted six-month data this month showing durable benefit for its patented psilocybin formulation in treatment-resistant depression — depression that hasn’t responded to at least two standard antidepressants — with launch targeted for 2027. MDMA’s path has been rockier: after the FDA’s 2024 rejection letter cited unreliable blinding (the drug’s intensity makes it obvious to both patient and therapist who got the real dose, undermining the placebo comparison that trials depend on), the company formerly known as Lykos, now Resilient Pharmaceuticals, quietly resubmitted its application last month without running the new Phase 3 trial regulators had asked for — a bet that two years and new FDA leadership changed the odds. And Texas, unwilling to wait on any of it, is spending $50 million of its own money to run its own ibogaine trials after private drug companies wouldn’t commit to the state’s terms. Three different institutions, three different timelines, one substance class, almost no coordination.

What this actually means if you’re not waiting for any of it

If you or someone you love is already using psilocybin, MDMA, or another psychedelic outside a licensed program — and statistically, if you’re using at all, you almost certainly are, since only two states have licensed anything — nothing announced today changes your situation. You’re not going to get a state-monitored center in most zip codes for years, if ever. What does exist right now, this week, is a harm reduction infrastructure built by nonprofits rather than agencies: organizations like DanceSafe run testing services at festivals and events specifically because unregulated supply means you genuinely cannot know potency or purity by looking at it, and integration support — someone to talk through a difficult experience afterward — exists through peer networks in most cities without requiring you to disclose anything to a clinician. None of that closes the gap the JAMA Psychiatry authors flagged. It’s just the actual safety net available to the actual population using the drug, as opposed to the smaller population a federal hearing is scoped to help.

The uncomfortable truth Washington keeps arranging its calendar around is that regulation always arrives after the behavior it’s regulating, and every year of delay gets absorbed by whoever’s already using — with whatever information and testing they can scrape together on their own. Four hours in a room in Silver Spring won’t change that arithmetic. It’ll just decide, eventually, who gets to skip it.